Characterizing the roles of RIF1 and 53BP1 in DNA double strand break repair pathways in the context of PARP1 inhibition

表征 PARP1 抑制背景下 RIF1 和 53BP1 在 DNA 双链断裂修复途径中的作用

• 批准号: 361556
• 负责人: Setiaputra Dheva T
• 金额: $ 9.83万
• 依托单位: Sinai Health System (Toronto)
• 依托单位国家: 加拿大
• 项目类别: Fellowship Programs
• 财政年份: 2016
• 资助国家: 加拿大
• 起止时间: 2016-11-01 至 2019-11-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=361556&lang=en
• 关键词: Cell Biology; Dna Damage Repair; Protein-Protein Interaction

Women carrying mutations in the BRCA1 gene has over 50% chance of developing breast cancer. A recent class of chemotherapeutics, poly ADP ribose polymerase 1 (PARP1) inhibitors, has shown promising results in BRCA1-mutated breast cancer. However, several

在BRCA1基因中携带突变的女性患乳腺癌的可能性超过50％。最近的化学治疗剂，Poly ADP核糖聚合酶1（PARP1）抑制剂，在BRCA1突变的乳腺癌中显示出令人鼓舞的结果。但是，有几个